Markets

Shire goes Viro

Shire is bolstering its rare diseases drug portfolio with a $4.2bn acquisition of ViroPharma. Lex's Nikki Tait and Vincent Boland discuss how this big buy fits with the pharmaceuticals company's cost drive.